Nov 3 (Reuters) -

Overview

* CareRx Q3 2025 revenue rose slightly but missed analyst expectations

* Adjusted EBITDA for Q3 2025 increased but missed analyst estimates

* Company had declared a C$0.02 per share dividend and renewed share buyback program

Outlook

* Company did not provide specific guidance for future quarters or full year in its press release

Result Drivers

* BED COUNT INCREASE - Average beds serviced increased, contributing to revenue and EBITDA growth

* COST SAVINGS - Adjusted EBITDA and margin growth attributed to cost savings initiatives and onboarding of new beds

* STRATEGIC INVESTMENTS - Co cites strategic investments in operating platform as contributing to growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss C$93.22 C$93.90

Revenue mln mln (3

Analysts

)

Q3 Net C$1.55

Income mln

Q3 Miss C$8.34 C$8.73

Adjusted mln mln (3

EBITDA Analysts

)

Q3 9%

Adjusted

EBITDA

Margin

Q3 C$7.71

EBITDA mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the drug retailers peer group is "buy"

* Wall Street's median 12-month price target for CareRx Corp ( CHHHF ) is C$4.25, about 15.5% above its October 31 closing price of C$3.59

* The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 16 three months ago

Press Release:

For questions concerning the data in this report, contact . For any other questions or feedback, contact .

(Reporting by Aby Jose Koilparambil in Bengaluru)